Education
Postdoctoral, McGill University AIDS Center, Canada
PhD, University of the Witwatersrand, South Africa
BSc (Honors), University of the Witwatersrand, South Africa
BSc, University of the Witwatersrand, South Africa
Academic Affiliation(s)
Associate Professor, Department of Medicine, Division of Infectious Diseases
Associate Professor, Department of Microbiology and Molecular Genetics
Associate Professor, Graduate School of Public Health, Department of Infectious Diseases and Microbiology
Member, Molecular Virology and Microbiology Graduate Program
Research
Dr Sluis-Cremer's research focuses on antiretroviral drugs, drug resistance and HIV latency. Projects include understanding the biochemistry and cellular biology of HIV reverse transcription, elucidating the mechanisms of action and resistance to HIV antiviral drugs, and the discovery of novel inhibitors active against drug resistant HIV-1. New initiatives include understanding the mechanisms involved in HIV latency and pharmacological approaches to eradicate latent HIV infection.
Lab Personnel
Kelly Huber, Research Specialist IV
Genevieve Doyon, Postdoctoral Fellow
Brian Herman, Postdoctoral Fellow
Jennifer Zerbato, Graduate Student
Areas of Interest
HIV; drug discovery; drug resistance; latency; persistence
Publications
Herman B. D, Schinazi R. F, Zhang H. W, Nettles J. H, Stanton R, Detorio M, Obikhod A, Pradere U, Coats S. J, Mellors J. W, and Sluis-Cremer N. Substrate mimicry: HIV-1 reverse transcriptase recognizes 6-modified-3'-azido-2',3'-dideoxyguanosine-5'-triphosphates as adenosine analogs. Nucleic Acids Res. 40: 381-390. | View Abstract
Doyon G, Zerbato J, Mellors J. W, and Sluis-Cremer N. Disulfiram reactivates latent HIV-1 expression through depletion of the phosphatase and tensin homolog (PTEN). AIDS. [epub ahead of print 6/29/12] | View Abstract
Brehm J. H, Scott Y, Koontz D. L, Perry S, Hammer S, Katzenstein D, Mellors J. W, Sluis-Cremer N. Zidovudine (AZT) monotherapy selects for the A360V mutation in the connection domain of HIV-1 reverse transcriptase. PLoS One. 7: e31558. | View Abstract
Huber, K, Doyon G, Plaks J, Fyne E, Mellors J. W, and Sluis-Cremer N. Inhibitors of histone deacetylases: correlation between isoform specificity and reactivation of HIV type 1 (HIV-1) from latently infected cells. J Biol Chem. 286: 22211-22218. | View Abstract
Sluis-Cremer N, Moore K, Radzio J, Sonza S, and Tachedjian G. N348I in HIV-1 reverse transcriptase decreases susceptibility to tenofovir and etravirine in combination with other resistance mutations. Aids. 24: 317-319. | View Abstract
Radzio J, Yap S. H, Tachedjian G, and Sluis-Cremer N. N348I in reverse transcriptase provides a genetic pathway for HIV-1 to select thymidine analogue mutations and mutations antagonistic to thymidine analogue mutations. Aids. 24: 659-667. | View Abstract
Sluis-Cremer N, Koontz D, Bassit L, Hernandez-Santiago B. I, Detorio M, Rapp K. L, Amblard F, Bondada L, Grier J, Coats S. J, Schinazi R. F, and Mellors J. W. Anti-human immunodeficiency virus activity, cross-resistance, cytotoxicity, and intracellular pharmacology of the 3'-azido-2',3'-dideoxypurine nucleosides. Antimicrob Agents Chemother. 53: 3715-3719. | View Abstract